Vital Signs The Analyst's Perspective - May 2016 Issue

USD 450.00

* Required Fields

USD 450.00


Be the first to review this product

This Vital Signs issue discusses Sinocare's acquisition of PTS Diagnostics, biosimilar drug pricing, Americans' usage of prescription pain killers, and Takara Bio's acquistion of Wafergen Bio-systems.

Table of Contents

Vital Signs The Analyst's Perspective - May 2016 IssueVital Signs - May 2016 IssueMay 2016 Issue

Why Frost & Sullivan

Working with the CEO’s growth team to create a vision based on a transformation growth strategy

Creating content-based digital marketing strategies that leverage our research perspective to differentiate and “tell your story”

Tracking over 1000 emerging technologies and analyzing the impact by industry and application to reveal the companies to watch in each sector

The Frost & Sullivan team is based in our 45 global offices and have developed a powerful global understandings of how industries operate on a global level.